Krzysztof Selmaj

Profesor

Uniwersytet Warminsko-Mazurski

Poland

Research Interests

Explore related searches

Professors in Poland

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Professor Krzysztof Selmaj is a faculty member at Uniwersytet Warminsko-Mazurski in Poland. His research primarily focuses on multiple sclerosis, including the efficacy and safety of various treatments and biomarkers associated with the disease. He has authored several recent articles addressing the long-term safety of new therapies and the impact of circRNA on disease mechanisms.

Articles (10)

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Collaborators (3)

Maria Pia Amato

University of Florence

ITALY

View details

Bruce Cree

Professor of Clinical Neurology

University of California, San Francisco

UNITED STATES

View details

Carmen Tur

University College London

SPAIN

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Krzysztof Selmaj

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5 years of follow-up in the DAYBREAK open-label extension trial

Efficacy and safety of temelimab in multiple sclerosis: Results of a randomized phase 2b and extension study

Fluid phase biomarkers in multiple sclerosis

Impact of Diminished Expression of circRNA on Multiple Sclerosis Pathomechanisms

Optical coherence tomography assessment of axonal and neuronal damage of the retina in patients with familial and sporadic multiple sclerosis

The risk of infections for multiple sclerosis and neuromyelitis optica spectrum disorder disease-modifying treatments: Eighth European Committee for Treatment and Research in Multiple Sclerosis Focused Workshop Review. April 2021

Treatment satisfaction, safety, and tolerability of cladribine tablets in patients with highly active relapsing multiple sclerosis: CLARIFY-MS study 6-month interim analysis

Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis

Use of follow-on disease-modifying treatments for multiple sclerosis: Consensus recommendations

Efficacy and safety of alemtuzumab over 6 years: final results of the 4-year CARE-MS extension trial

Collaborators (3)

Maria Pia Amato

Bruce Cree

Carmen Tur

Make your next move.